The brand name for moexipril is Univasc [1].
What is Univasc (moexipril) used for?
Univasc is an angiotensin-converting enzyme (ACE) inhibitor prescribed to treat high blood pressure (hypertension) [2]. It works by relaxing blood vessels, which helps to lower blood pressure and reduce the workload on the heart [2].
How does moexipril work?
Moexipril functions by inhibiting the angiotensin-converting enzyme. This enzyme is responsible for converting angiotensin I to angiotensin II, a potent vasoconstrictor. By blocking this conversion, moexipril leads to vasodilation (widening of blood vessels) and a reduction in aldosterone secretion, both of which contribute to lowering blood pressure [2].
When does the patent for Univasc expire?
Information regarding the specific patent expiration date for Univasc is available through resources like DrugPatentWatch.com [1]. Patent expirations are crucial for the potential entry of generic versions of the medication [1].
Can generic versions of moexipril be made?
Yes, once patent protections expire, generic versions of moexipril can be manufactured and marketed. The availability of generics typically leads to lower medication costs for consumers [1].
What are the side effects of moexipril?
Common side effects associated with moexipril (Univasc) can include dizziness, headache, fatigue, cough, and nausea [2]. More serious side effects, though less common, may include angioedema (swelling of the face, lips, tongue, or throat) and kidney problems [2]. It is important to discuss any concerns about side effects with a healthcare provider.
How does moexipril compare to other ACE inhibitors?
Moexipril belongs to the ACE inhibitor class of drugs, which includes others such as lisinopril, enalapril, and ramipril. While they share a similar mechanism of action in treating hypertension, individual drugs within the class may differ in their pharmacokinetic profiles, dosing regimens, and potential side effect profiles [3]. The choice of ACE inhibitor is often individualized based on patient response and tolerance.
Who manufactures Univasc?
Univasc (moexipril) was originally developed and marketed by Daiichi Sankyo [4].
---
Sources:
[1] DrugPatentWatch.com
[2] RxList.com
[3] MedlinePlus
[4] Drugbank.ca